Panelists discuss the evolving disease burden and health equity challenges of hidradenitis suppurativa, recent therapeutic advancements, and the comprehensive economic impact, highlighting opportunities for improved clinical outcomes and cost-effective, equitable care.
July 18th 2025EP. 1: Recognizing Hidradenitis Suppurativa: From First Signs to an Accurate Diagnosis
Panelists discuss the challenges of timely diagnosis and comprehensive management of hidradenitis suppurativa, emphasizing the need for early recognition, multidisciplinary care, and empathy-centered approaches to address the physical, emotional, and social burden of the disease.
Panelists discuss the drivers and consequences of delayed diagnosis in hidradenitis suppurativa, emphasizing the need for provider education, clinical decision support, and multidisciplinary collaboration to promote earlier recognition and more effective, coordinated care.
July 25th 2025EP. 3: The Pharmacist Advantage: Bridging Gaps in Hidradenitis Suppurativa Care
Panelists discuss the vital role of multidisciplinary collaboration, provider education, and technology integration in improving early diagnosis and comprehensive management of hidradenitis suppurativa, highlighting how coordinated efforts across specialties—including pharmacists—can reduce delays, enhance equity, and optimize patient outcomes.
July 25th 2025EP. 4: Health Equity in Hidradenitis Suppurativa: Addressing Care Disparities
Panelists discuss the significant disparities in hidradenitis suppurativa diagnosis and care, emphasizing the impact of race, gender, geography, and socioeconomic status, and highlighting the need for culturally competent education, expanded access, and community engagement to promote earlier intervention and equitable outcomes.
Panelists discuss optimizing hidradenitis suppurativa management through early intervention, personalized treatment based on disease severity, and multidisciplinary coordination led by dermatologists to improve patient outcomes and reduce disease burden.
Panelists discuss the importance of coordinated, personalized treatment strategies for hidradenitis suppurativa, highlighting early use of pharmacologic therapies—including biologics—and ongoing assessment to balance clinical effectiveness, patient quality of life, and financial considerations.